Omeros (OMER) Amortization of Deferred Charges (2018 - 2026)
Omeros (OMER) posted Amortization of Deferred Charges of -$7.8 million for Q4 2025, down 633.88% sequentially from $1.5 million in Q3 2025, and down 6.05% YoY from -$8.3 million in Q4 2024.
Analysis
Omeros (OMER) Amortization of Deferred Charges (2018 - 2026) Analysis & Trends
Omeros has reported Amortization of Deferred Charges for 8 years, with the latest figure at -$7.8 million in Q4 2025.
- Quarterly Amortization of Deferred Charges fell 6.05% year-over-year to -$7.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$6.2 million (up 5.39% YoY) and the FY2025 annual result came in at -$5.6 million, down 19.16% from the prior year.
- Amortization of Deferred Charges declined to -$7.8 million in Q4 2025 per OMER's latest filing, from $1.5 million in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.1 million in Q3 2024 and troughed at -$7.8 million in Q4 2025.
- A 5-year average of -$585631.6 and a median of $440000.0 in 2021 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2022 and 2024: Amortization of Deferred Charges tumbled 409.32% in 2022, then jumped 319.55% in 2024.
- Over 5 years, Amortization of Deferred Charges stood at $440000.0 in 2021, then sank by 409.32% to -$1.4 million in 2022, then fell by 6.54% to -$1.4 million in 2023, then plunged by 406.21% to -$7.3 million in 2024, then slipped by 6.05% to -$7.8 million in 2025.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered -$7.8 million, $1.5 million, and $92000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.44 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | -10.31 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | 1.31 Mn |
| Mar 31, 2025 | -1.91 Mn |
| Dec 31, 2024 | -7.34 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 599,000.00 |
| Mar 31, 2024 | 1.39 Mn |
| Dec 31, 2023 | 403,000.00 |
| Sep 30, 2023 | 491,000.00 |
| Jun 30, 2023 | 482,000.00 |
| Mar 31, 2023 | 477,000.00 |
| Dec 31, 2022 | 469,000.00 |
| Sep 30, 2022 | 461,000.00 |
| Jun 30, 2022 | 454,000.00 |
| Mar 31, 2022 | 446,000.00 |
| Dec 31, 2021 | 440,000.00 |
| Sep 30, 2021 | 434,000.00 |